Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 8/20 | 0.34 |
| ▸ | KIF11 | P52732 | 3/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.32 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.32 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4981017 | 0.77 | CTSA (0.40) | BDKRB1 | |
| SCHEMBL4988410 | 0.76 | BDKRB1 (0.36) | BDKRB1 | |
| SCHEMBL4988407 | 0.73 | BDKRB1 (0.35) | BDKRB1ALOX5APFEN1 | |
| Hydrochloric Acid SCHEMBL4983756 | 0.70 | GRIA4 (0.36) | BDKRB1ALOX5APFEN1 | |
| SCHEMBL4983690 | 0.67 | DGAT1 (0.39) | — | |
| SCHEMBL4987228 | 0.66 | BDKRB1 (0.71) | BDKRB1 | |
| SCHEMBL4683497 | 0.63 | KDM4E (0.50) | — | |
| SCHEMBL4374632 | 0.61 | GUCY1B2 (0.36) | PTGS2 | |
| SCHEMBL4985174 | 0.60 | ROCK1 (0.41) | — | |
| SCHEMBL4374146 | 0.58 | KMT2A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332499-B2 | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides | MERCK & CO., INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060247229-A1 | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides | MERCK SHARP & DOHME CORP. | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247229-A1 | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides | BDKRB1, BDKRB2, CNR2 | BDKRB1 1/4885KIF11 4733/4885SCN9A 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.